Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials

Dr. Valentin Fuster discusses a study on the efficacy of semaglutide for treating obesity-related heart failure with preserved ejection fraction, highlighting that the drug significantly reduced body weight and improved heart failure symptoms in both men and women. Notably, women experienced greater weight loss than men, but this did not translate into better improvement in heart failure-related symptoms, underscoring complex sex-related differences in cardiovascular health.